DiscoveRx, a Leader in GPCR Assays, Launches a 30 Second Assay for Beta-Arrestin Based ScreeningWith the PathHunter(TM) Flash Detection Kit
DiscoveRx, a Leader in GPCR Assays, Launches a 30 Second Assay for Beta-Arrestin Based ScreeningWith the PathHunter(TM) Flash Detection Kit, beta-arrestin recruitment by a GPCR can now be detected in 30 seconds, permitting screens of up to 1,000,000 compounds in 48 hours. Unlike lengthy reporter gene assays, PathHunter beta-arrestin assays are direct and hence minimize the opportunity for off-target effects. A ligand-activated, GPCR-arrestin interaction combines two beta-galactosidase fragments, enabling rapid chemiluminescent detection in a homogeneous format. The kit is designed for whole class of plate readers with onboard fluidics and flash detection mode.
With the PathHunter(TM) Flash Detection Kit, beta-arrestin recruitment by a GPCR can now be detected in 30 seconds, permitting screens of up to 1,000,000 compounds in 48 hours. Unlike lengthy reporter gene assays, PathHunter beta-arrestin assays are direct and hence minimize the opportunity for off-target effects. A ligand-activated, GPCR-arrestin interaction combines two beta-galactosidase fragments, enabling rapid chemiluminescent detection in a homogeneous format. The kit is designed for whole class of plate readers with onboard fluidics and flash detection mode.
Additionally, screening campaigns can be accelerated by conducting beta-arrestin and calcium assays in the same well on same instrument, without need of cell fixation, when using instruments capable of real-time fluorescence and flash chemiluminescence. The ability to run intracellular calcium assays in combination with the homogeneous, chemiluminescent PathHunter beta-Arrestin assay helps drive the costs of primary screening campaigns down while significantly increasing the speed of compound characterization. Either run alone or in combination with calcium mobilization, with launch of the Flash Kit, GPCR Screening has now become even faster. With an expanding list of GPCR Beta-Arrestin assays (greater than 90 assays) being added to its product offering, DiscoveRx has a solution for virtually any GPCR screening campaign. Standard chemiluminescent detection for batch mode processing or flash detection for kinetic measurements, we have a solution for you! Call us to discuss your GPCR screening needs!
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of beta-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. The Company is also the recipient of Frost and Sullivan’s prestigious 2006 Award for Technology Innovation. This award was given in recognition for successful introduction of PathHunter(TM) cell-based assay platform and company’s overall work on intact and/or lysed cell based assays. For more information on DiscoveRx products, please visit www.discoverx.com
